In patients with moderate persistent asthma and elevated FeNO despite adequate symptom control on omalizumab and ICS-LABA, would you consider switching to another biologic such as dupilumab or tezepelumab?
1 Answers
Mednet Member
Allergy & Immunology · Emory University Hospital
If they have adequate symptom control, not sure I would switch. If I did switch, I would. Consider Dupiumab or an anti-IL5 or IL5R blocker given the Type 2 inflammation detected by elevated FeNO.
